2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials
Karen A. Hicks(Center for Drug Evaluation and Research), Shari Targum(Center for Drug Evaluation and Research), Roxana Mehran(Icahn School of Medicine at Mount Sinai), Biykem Bozkurt(Medical University of South Carolina), Judith H. Lichtman(American Heart Association), Andrew Farb(Memorial Hermann), Jeffrey P. Jacobs(Jacobs (Spain)), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Steven E. Nissen(Cleveland Clinic), Donald E. Cutlip(Beth Israel Deaconess Medical Center), Michael R. Jaff(Harvard University), Gregg C. Fonarow, Bernard Chaitman(Saint Louis University), Marian C. Limacher(Marian University - Indiana), James E. Tcheng(Duke University), Eric E. Smith(University of Calgary)
Cited by 702
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
|Circulation|2020|9.4k
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
|Circulation|2019|9.1k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k